Loading
Fifteen months of two pills, then stop: three-quarters of patients had no detectable leukaemia in the blood, and most remained in remission years later.
Fixed-duration cohort: CR 55% (primary endpoint met), uMRD in blood 77%, 4-year PFS ~79% (2024 update), retreatment with ibrutinib effective at relapse. MRD-guided cohort tested stopping vs continuing in confirmed uMRD (no PFS difference at 3 years). Blood 2022; JCO 2024. Basis (with GLOW) of the EU approval of fixed-duration ibrutinib-venetoclax.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
323 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete response (fixed-duration cohort)primary | Ibrutinib + venetoclax | 159 | 55% | - | - | link |
| Undetectable MRD in peripheral blood | Ibrutinib + venetoclax | - | 77% | - | - | link |
Shares BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, Ibrutinib.
Shares MRD-guided treatment duration in CLL, BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment.
Shares Chronic lymphocytic leukaemia, first treatment, Ibrutinib, AbbVie (incl. ImmunoGen, Capstan), Venetoclax.
Shares BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares MRD-negative complete remission, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, Ibrutinib.
Shares BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, Ibrutinib, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Ibrutinib, AbbVie (incl. ImmunoGen, Capstan), Chronic lymphocytic leukaemia.